/
Nephrology
Nephropathy
101
Pipeline Programs↗
124
Active Trials↗
82
Companies Involved↗
Nephropathy is a highly competitive landscape with 101 programs across 82 companies. The most active players are Otsuka, Keymed Biosciences Co.Ltd, NovelMed Therapeutics. 32 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical43
Phase 14
Phase 222
Phase 332
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
86 of 96 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 96 classified programs, each share of the total. Modality classified for 98% of 101 pipeline programs.
Analysis
Trial Status
478
clinical trials
Completed220 · 46%
Unknown status83 · 17%
Recruiting59 · 12%
Not yet recruiting40 · 8%
Terminated35 · 7%
Active, not recruiting21 · 4%
Other20 · 4%
Clinical Trials
Trial Activity
478 trials
Development and Validation of a Gd-IgA1 Guided Precision Therapy System for Targeted Therapeutic Strategies of IgA Nephropathy： An Open-label, Random Controlled Trial
Recruiting·—·Preclinical·NCT07822100·374 enrolled
Page 1 of 32
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)